Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
2019 ◽
2019 ◽
2019 ◽
Vol 7
(1)
◽
pp. 14-14
◽
2009 ◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3074-3074
◽
2006 ◽
Vol 66
(15)
◽
pp. 7708-7715
◽